, Volume 24, Issue 6, pp 379–386


In Cancer Treatment-Induced Bone Loss
Adis Drug Profile


Denosumab is a fully human monoclonal IgG2 antibody that binds to receptor activator of nuclear factor-κB ligand (RANKL) and inhibits bone resorption due to RANKL-mediated osteoclas-togenesis. In Europe, subcutaneous denosumab is indicated for cancer treatment-induced bone loss in men with prostate cancer and in postmenopausal women with breast cancer.

In a large (n=1468), well designed, multinational, phase III trial in adult patients with prostate cancer who were receiving androgen-deprivation therapy, bone mineral density (BMD) at the lumbar spine was significantly improved from baseline after 24 (primary endpoint) and 36 months of treatment with subcutaneous denosumab (60 mg once every 6 months), relative to that with placebo. Moreover, the risk of new vertebral fracture was significantly reduced by 62% in the denosumab group compared with the placebo group.

In breast cancer patients receiving aromatase inhibitor therapy (n = 252), subcutaneous denosumab (60mg once every 6 months) significantly improved BMD at the lumbar spine from baseline after 12 (primary endpoint) and 24 months of treatment relative to placebo in a pivotal phase III trial.

There were significant improvements in BMD at all skeletal sites, including the lumbar spine, total hip, and femoral neck, after 24 and 36 months' denosumab treatment in prostate cancer patients and after 12 and 24 months’ treatment in breast cancer patients. In general, these improvements occurred irrespective of baseline characteristics, including age, duration of hormone ablation therapy, and baseline BMD.

Denosumab treatment was generally well tolerated for up to 24 months in breast cancer patients and for up to 36 months in prostate cancer patients.


  1. 1.
    Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 Mar; 18(3): 581–92PubMedCrossRefGoogle Scholar
  2. 2.
    American Cancer Society. Cancer facts and figures 2010 [online]. Available from URL: [Accessed 2010 Aug 18]
  3. 3.
    Michaud LB. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 2010; 67Suppl. 3: S20–30PubMedCrossRefGoogle Scholar
  4. 4.
    Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 2003; 20(3): 175–83PubMedCrossRefGoogle Scholar
  5. 5.
    Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007 Jun; 14(3): 247–54PubMedCrossRefGoogle Scholar
  6. 6.
    Berruti A, Tucci M, Terrone C, et al. Background to and management of treatment-related bone loss in prostate cancer. Drugs Aging 2002; 19(12): 899–910PubMedCrossRefGoogle Scholar
  7. 7.
    Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009 Aug; 20(8): 1319–29PubMedCrossRefGoogle Scholar
  8. 8.
    Aebi S, Davidson T, Gruber G, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21Suppl. 5: v9–14PubMedCrossRefGoogle Scholar
  9. 9.
    Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005 Jan 20; 23(3): 619–29PubMedCrossRefGoogle Scholar
  10. 10.
    Pant S, Shapiro CL. Aromatase inhibitor-associated bone loss: clinical considerations. Drugs 2008; 68(18): 2591–600PubMedCrossRefGoogle Scholar
  11. 11.
    Lonning PE. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)? J Clin Oncol 2008 Oct 20; 26(30): 4859–61PubMedCrossRefGoogle Scholar
  12. 12.
    Lattouf JB, Saad F. Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Curr Opin Urol 2010 May; 20(3): 247–52PubMedCrossRefGoogle Scholar
  13. 13.
    Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. Ann Pharmacother 2009 Sep; 43(9): 1445–55PubMedCrossRefGoogle Scholar
  14. 14.
    Smith M. RANK ligand-targeted therapy: a novel approach to prevent bone loss and fractures in men with prostate cancer. Eur Urol Suppl 2009; 8(11): 834–8CrossRefGoogle Scholar
  15. 15.
    Romas E. Clinical applications of RANK-ligand inhibition. Intern Med J 2009 Feb; 39(2): 110–6PubMedCrossRefGoogle Scholar
  16. 16.
    Tanko L. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe? Curr Opin Invest Drug 2007; 8(10): 830–5Google Scholar
  17. 17.
    Miller K, Stenzl A, Tombal B. Advances in the therapy of prostate cancer-induced bone disease: current insights and future perspectives on the RANK/RANKL pathways. Eur Urol Suppl 2009; 8(9): 747–52CrossRefGoogle Scholar
  18. 18.
    Amgen Incorporated. Prolia (denosumab) summary of product characteristics [online]. Available from URL: [Accessed 2010 May 31]
  19. 19.
    European Medicines Agency. CHMP assessment report for Prolia [online]. Available from URL: [Accessed 2010 Jun 25]
  20. 20.
    Amgen Incorporated. Prolia (denosumab) prescribing information [online]. Available from URL: [Accessed 2010 Jun 6]
  21. 21.
    Kostenuik PJ, Nguyen H, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24(2): 182–95PubMedCrossRefGoogle Scholar
  22. 22.
    Gerstenfeld L, Sacks D, Pelis M, et al. Comparison of effects of the bisphos-phonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009; 24(2): 196–208PubMedCrossRefGoogle Scholar
  23. 23.
    Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361(8): 745–55PubMedCrossRefGoogle Scholar
  24. 24.
    Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008 Oct 20; 26(30): 4875–82PubMedCrossRefGoogle Scholar
  25. 25.
    Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19(7): 1059–66PubMedCrossRefGoogle Scholar
  26. 26.
    McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006 Feb 23; 354(8): 821–31PubMedCrossRefGoogle Scholar
  27. 27.
    Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93(6): 2149–57PubMedCrossRefGoogle Scholar
  28. 28.
    Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009 Jan; 24(1): 153–61PubMedCrossRefGoogle Scholar
  29. 29.
    Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25(1): 72–81PubMedCrossRefGoogle Scholar
  30. 30.
    Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009 Aug 20; 361(8): 756–65PubMedCrossRefGoogle Scholar
  31. 31.
    Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008 Aug; 43(2): 222–9PubMedCrossRefGoogle Scholar
  32. 32.
    US Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs (August 13, 2009) [online]. Available from URL: [Accessed 2010 Apr 19]
  33. 33.
    Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008 Jun; 99(6): 1237–42PubMedCrossRefGoogle Scholar
  34. 34.
    Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12(4): 1221–8PubMedCrossRefGoogle Scholar
  35. 35.
    Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27(10): 1564–71PubMedCrossRefGoogle Scholar
  36. 36.
    Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 2008 Aug; 326(2): 555–62PubMedCrossRefGoogle Scholar
  37. 37.
    Rodriguez RD, Sutjandra L, Peterson MC, et al. Population pharmacokinetics of denosumab, a monoclonal antibody that inhibits bone resorption, in healthy and cancer subjects and postmenopausal women with osteopenia or osteoporosis [abstract no. 278]. AAPS J 2009; 11 Suppl. 1Google Scholar
  38. 38.
    Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182(6): 2670–5PubMedCrossRefGoogle Scholar
  39. 39.
    Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009; 118(1): 81–7PubMedCrossRefGoogle Scholar
  40. 40.
    Smith MR, Egerdie B, Sieber P, et al. Prevalent vertebral fracture and survival in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer [abstract no. 25]. Genitourinary Cancers Symposium; 2010 Mar 5-7; San Francisco (CA)Google Scholar
  41. 41.
    Amgen Incorporated. A study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen-deprivation therapy [ identifier NCT00925600]. US National Institutes of Health, [online]. Available from URL: [Accessed 2010 May 6]

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North ShoreNew Zealand

Personalised recommendations